Literature DB >> 9263538

Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines.

A Hara1, N Yoshimi, M Niwa, N Ino, H Mori.   

Abstract

Recent studies have suggested that apoptosis is a key phenomenon in the chemopreventive action of nonsteroidal antiinflammatory drugs (NSAIDs), which exhibit cancer-preventive and tumor-regressive effects in the human colon. The effect of NS-398, N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide, which is a selective inhibitor of cyclooxygenase-2 (COX-2), on the induction of apoptosis in two human colorectal cancer cell lines (Colo320 and THRC) was determined. The apoptotic ratios (-fold vs. control value) of Colo320 in the presence of 100 microM indomethacin and NS-398 were 3.3 +/- 1.5 and 9.0 +/- 0.94, and those of THRC were 2.3 +/- 0.46 and 7.4 +/- 0.87, respectively. The ability of NS-398 to induce apoptosis is greater than that of indomethacin. Both indomethacin and NS-398 reduced the cell proliferation in a concentration-dependent manner. The IC50 values of NS-398 (54.8 +/- 3.6 and 77.2 +/- 4.9 microM) were significantly lower than those of indomethacin (206.3 +/- 43.0 and 180.3 +/- 22.6 microM) at P < 0.01 in Colo320 and THRC cell lines, respectively. These findings suggest that NS-398, a selective inhibitor of COX-2, is a possible candidate for a chemopreventive agent with a potent apoptosis-inducing effect and low ulcerogenic activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9263538      PMCID: PMC5921468          DOI: 10.1111/j.1349-7006.1997.tb00424.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  19 in total

1.  Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes.

Authors:  K S Sellins; J J Cohen
Journal:  J Immunol       Date:  1987-11-15       Impact factor: 5.422

2.  Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines.

Authors:  B G Heerdt; M A Houston; L H Augenlicht
Journal:  Cancer Res       Date:  1994-06-15       Impact factor: 12.701

3.  Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis.

Authors:  S J Shiff; M I Koutsos; L Qiao; B Rigas
Journal:  Exp Cell Res       Date:  1996-01-10       Impact factor: 3.905

4.  Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.

Authors:  F M Giardiello; S R Hamilton; A J Krush; S Piantadosi; L M Hylind; P Celano; S V Booker; C R Robinson; G J Offerhaus
Journal:  N Engl J Med       Date:  1993-05-06       Impact factor: 91.245

5.  Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase?

Authors:  D S Alberts; L Hixson; D Ahnen; C Bogert; J Einspahr; N Paranka; K Brendel; P H Gross; R Pamukcu; R W Burt
Journal:  J Cell Biochem Suppl       Date:  1995

6.  NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro.

Authors:  N Futaki; S Takahashi; M Yokoyama; I Arai; S Higuchi; S Otomo
Journal:  Prostaglandins       Date:  1994-01

7.  Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis.

Authors:  G A Piazza; A L Rahm; M Krutzsch; G Sperl; N S Paranka; P H Gross; K Brendel; R W Burt; D S Alberts; R Pamukcu
Journal:  Cancer Res       Date:  1995-07-15       Impact factor: 12.701

Review 8.  Epidemiologic evidence on the association between peptic ulceration and antiinflammatory drug use.

Authors:  M J Langman
Journal:  Gastroenterology       Date:  1989-02       Impact factor: 22.682

9.  Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent.

Authors:  C V Rao; A Rivenson; B Simi; E Zang; G Kelloff; V Steele; B S Reddy
Journal:  Cancer Res       Date:  1995-04-01       Impact factor: 12.701

10.  Enhanced secretion of prostaglandin E2 by tissue-fixed macrophages in colonic carcinoma.

Authors:  W J Maxwell; D Kelleher; J J Keating; F P Hogan; F J Bloomfield; G S MacDonald; P W Keeling
Journal:  Digestion       Date:  1990       Impact factor: 3.216

View more
  15 in total

Review 1.  Chemopreventive potential of natural compounds in head and neck cancer.

Authors:  Mohammad Aminur Rahman; A R M Ruhul Amin; Dong M Shin
Journal:  Nutr Cancer       Date:  2010       Impact factor: 2.900

2.  Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer.

Authors:  Hiroyuki Konno; Megumi Baba; Tuyoshi Shoji; Manabu Ohta; Shohati Suzuki; Satoshi Nakamura
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

3.  Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors.

Authors:  T Kusaba; T Nakayama; K Yamazumi; Y Yakata; A Yoshizaki; T Nagayasu; I Sekine
Journal:  J Clin Pathol       Date:  2005-08       Impact factor: 3.411

4.  Specific COX-2 inhibitor NS398 induces apoptosis in human liver cancer cell line HepG2 through BCL-2.

Authors:  Dong-Sheng Huang; Ke-Zhen Shen; Jian-Feng Wei; Ting-Bo Liang; Shu-Sen Zheng; Hai-Yang Xie
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

5.  Potential pathogenetic implications of cyclooxygenase-2 overexpression in B chronic lymphoid leukemia cells.

Authors:  Paola Secchiero; Elisa Barbarotto; Arianna Gonelli; Mario Tiribelli; Carlotta Zerbinati; Claudio Celeghini; Claudio Agostinelli; Stefano A Pileri; Giorgio Zauli
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

Review 6.  Strategies for Improving Photodynamic Therapy Through Pharmacological Modulation of the Immediate Early Stress Response.

Authors:  Daniel J de Klerk; Mark J de Keijzer; Lionel M Dias; Jordi Heemskerk; Lianne R de Haan; Tony G Kleijn; Leonardo P Franchi; Michal Heger
Journal:  Methods Mol Biol       Date:  2022

Review 7.  Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis.

Authors:  O C Trifan; T Hla
Journal:  J Cell Mol Med       Date:  2003 Jul-Sep       Impact factor: 5.310

8.  Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosis.

Authors:  N A Mohammed; S A Abd El-Aleem; H A El-Hafiz; R F T McMahon; S A El-Aleem
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

9.  Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus.

Authors:  Pradeep Bhandari; Adrian C Bateman; Raj L Mehta; Bernard Sf Stacey; Penny Johnson; Ian A Cree; Federica Di Nicolantonio; Praful Patel
Journal:  BMC Cancer       Date:  2006-05-19       Impact factor: 4.430

10.  Toward Multitasking Pharmacological COX-Targeting Agents: Non-Steroidal Anti-Inflammatory Prodrugs with Antiproliferative Effects.

Authors:  Fedora Grande; Francesca Giordano; Maria Antonietta Occhiuzzi; Carmine Rocca; Giuseppina Ioele; Michele De Luca; Gaetano Ragno; Maria Luisa Panno; Bruno Rizzuti; Antonio Garofalo
Journal:  Molecules       Date:  2021-06-28       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.